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This manuscript describes the Child Health and Mortality Prevention Surveillance (CHAMPS) network approach to pathologic 
evaluation of minimally invasive tissue sampling (MITS) specimens, including guidelines for histopathologic examination and fur-
ther diagnostics with special stains, immunohistochemistry, and molecular testing, as performed at the CHAMPS Central Pathology 
Laboratory (CPL) at the Centers for Disease Control and Prevention, as well as techniques for virtual discussion of these cases 
(telepathology) with CHAMPS surveillance locations. Based on review of MITS from the early phase of CHAMPS, the CPL has 
developed standardized histopathology-based algorithms for achieving diagnoses from MITS and telepathology procedures in con-
junction with the CHAMPS sites, with the use of whole slide scanners and digital image archives, for maximizing concurrence and 
knowledge sharing between site and CPL pathologists. These algorithms and procedures, along with lessons learned from initial 
implementation of these approaches, guide pathologists at the CPL and CHAMPS sites through standardized diagnostics of MITS 
cases, and allow for productive, real-time case discussions and consultations.
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Though the under-5 mortality rate has decreased globally, the gap 
in child mortality rates between high-income and low-income 
countries remains large. In 2017, the under-5 mortality rate in 
low-income countries was 69 deaths per 1000 live births, and 
neonatal deaths accounted for 46% of under-5 deaths in 2016 
[1]. Laboratory testing is critical in diagnosing infectious disease 
during investigation of an infant or child death. Traditionally, etio-
logic agents of fatal infectious diseases were diagnosed by autopsy 
in conjunction with microbial culture of tissues, when performed. 
However, hospital autopsy rates are in decline [2], and the sensi-
tivity and specificity of microbiological methods such as culture 
may be affected by antemortem treatments or postmortem con-
tamination. As a result, the ability to detect and correctly identify 
the cause(s) of fatal pediatric infections has been reduced; clin-
ical diagnostic errors might be missed, opportunities to improve 
medical treatment might be lost, and healthcare statistics might be 
biased. Deaths associated with nonspecific signs and symptoms, 
and those occurring in the community, are the most challenging 
and are common among pediatric deaths. Knowledge about the 
cause of death and etiology-specific contributions is important for 
selecting strategies to further reduce infant mortality [3].
The continuing development of innovative diagnostic tech-
niques has been essential to infectious disease diagnoses and for 
determining causes of death; however, there are substantial dis-
parities between antemortem and postmortem diagnoses [4]. At 
the same time, clinical autopsy rates, including perinatal autop-
sies, have declined for multiple reasons, including low number 
and time constraints of pathologists, less promotion by phys-
icians, and refusal by bereaved families [5]. Nonetheless, patho-
logic evaluation is critical to accurately determine the cause of 
an individual’s death, and also for detection, surveillance, and 
research of emerging and reemerging pathogens. To help bridge 
this gap, minimally invasive tissue sampling (MITS) methods are 
being developed as a potential substitute for conventional autop-
sies [4, 6, 7]. The MITS technique is implemented by the Child 
Health and Mortality Prevention Surveillance (CHAMPS) pro-
ject, and represents the first use of MITS for the purpose of longi-
tudinal mortality surveillance in a large number of case patients 
without comparison of MITS with traditional autopsy specimens 
[4, 8–11]. CHAMPS is also unique in that it employs the use of 
many different laboratories and pathologists from vastly different 
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locations, and with different backgrounds and infrastructure, 
with the goals of determining causes of death and building pa-
thology capacity in each country associated with the project. 
Given these complexities, it was essential to develop standard-
ized methods for histopathologic evaluation and further testing 
of MITS, and for achieving concordance and knowledge sharing 
between sites through telepathology.
HISTOPATHOLOGICAL EVALUATION OF MITS: 
DEVELOPMENT OF STANDARDIZED CHECKLISTS
Given the multicentric nature of the CHAMPS study and the varia-
bility in the associated pathologists’ backgrounds, along with the po-
tential variety of pathogenic processes to be encountered, it was critical 
to develop a standardized checklist of potential histopathologic find-
ings for each tissue type to ensure thorough, systematic, and com-
parable review of all cases. These checklists were developed jointly 
by the CHAMPS Central Pathology Laboratory (CPL) and partners 
in conjunction with CHAMPS sites, and incorporate information 
obtained from histopathologic features commonly observed in a 
pilot study. Sample checklists for liver, lung, and brain are provided 
in Supplementary Figures 1A–C. For each, there is a list of detailed 
tissue-specific findings and a separate list of tissue-specific overall 
diagnoses to be evaluated by the pathologist. Importantly, checklists 
also include measures of overall sample quality, including technical 
adequacy of target tissue collection, indicated by number of cores or 
core fragments of target tissue present (Figure 1A and 1B). Other 
measures of sample quality include tissue autolysis, postmortem 
bacterial overgrowth, presence of pertinent tissue components (eg, 
meninges in brain specimens), and contamination (Figure 1C–F). 
Spaces are also available to describe incidental tissues present and to 
document testing to be completed in each case.
ALGORITHMS FOR INFECTIOUS DISEASE TESTING 
OF MITS
Different infectious agents can cause characteristic but nonspe-
cific inflammatory responses in tissues, which depend on (1) 
Figure 1. Examples of technical challenges often encountered in the microscopic examination of minimally invasive tissue sampling (MITS) cases. A, Lung sample showing 
5 core fragments, which is considered adequate for evaluation. An “adequate” sample is defined as when at least 2 full cores worth of target tissue are present. B, Lung 
sample showing 1 small fragment of lung (circle) with no significant findings and fragments of skeletal muscle, which is an inadequate sample (<1 core fragment). An “inade-
quate” sample is defined as either no target tissue present, or <2 cores of target tissue present with no significant findings. C and D, Liver histopathology shows autolysis (C) 
in macerated fetus and normal liver (D) in early neonate for comparison. E, Brain tissue from central nervous system posterior sampling showing meninges (arrow), which are 
important for evaluating brain MITS for infectious processes; F, Brain tissue with nasal content (*) introduced during sampling. Nasal content includes mucous, neutrophilic 
inflammation, and yeasts.
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the anatomy of the affected organ and route of pathogen entry; 
(2) virulence factors associated with the pathogen (ability to 
gain access to host, biologic products that damage host cells); 
and (3) host response (intrinsic host defenses and innate im-
munity, adaptive immunity and immunocompetence, genetic 
predisposing factors). Conversely, a single microorganism can 
elicit a variety of different patterns of inflammation (eg, pneu-
mococcal pneumonia vs pneumococcal sepsis). Furthermore, 
other laboratory methods, such as culture and multiplex poly-
merase chain reaction (PCR) (TaqMan Array Card [TAC] in the 
case of CHAMPS; see Diaz et al in this supplement]) performed 
on autopsy specimens, can yield multiple possible causative 
agents for consideration or exclusion as a cause of the observed 
histopathologic changes seen. To clarify laboratory testing re-
sults, demonstration of a microorganism by special stains, 
immunohistochemistry (IHC), and/or PCR within lesions 
observed in the tissues provides support or confirmation of cau-
sation, while lack of detection by these methods may suggest ab-
sence of the agent or low sensitivity of the assay in formalin-fixed, 
paraffin-embedded (FFPE) tissue, detection of commensals 
or contaminants, or sampling discrepancy. Given the potential 
wide variety of pathogens on the list of differential diagnoses in 
CHAMPS MITS specimens, algorithms for infectious disease 
testing were developed using a syndromic approach, in an at-
tempt to incorporate and standardize the use of all the various 
testing modalities employed in this project. These algorithms 
were based on histopathologic patterns of disease most com-
monly encountered in a CHAMPS pilot study: bronchopneu-
monia, interstitial pneumonia, meningitis, sepsis, and aspiration 
in stillbirth or early neonate deaths (Figures 2–6). More than 1 
algorithm may be applicable in CHAMPS cases (eg, pneumonia 
and sepsis). In general, algorithms start with histopathologic 
Figure 2. Algorithm for evaluation of bronchopneumonia in minimally invasive tissue samples from children aged <5 years. Bronchopneumonia is characterized by neutro-
philic infiltrates within air spaces and prompts performing special stains (Gram, Warthin-Starry [W-S], Grocott methenamine silver [GMS]) to evaluate for bacteria or, less 
commonly, other agents such as fungi. If special stains are positive (POS) (right side of algorithm) (1), immunohistochemistry (IHC) is performed for relevant agents with 
compatible morphology and special stain characteristics seen. (Agents detected on lung TaqMan Array Card [TAC] with compatible features seen by special stains should be 
included in IHC testing.) If these special stains and TAC-guided IHC are negative (2), paneubacterial 16S polymerase chain reaction (PCR) with sequencing and additional IHC 
testing (*) to include Streptococcus species and select gram-negative (GN) bacteria are performed on the formalin-fixed, paraffin-embedded (FFPE) tissue. (Select GN bacterial 
IHC assay uses an antibody raised against Klebsiella pneumoniae but is also known to detect Escherichia coli, Haemophilus influenzae, and Pseudomonas species, among 
others. Immunostaining with this antibody is interpreted in conjunction with results of other tests [ie, TAC, FFPE-based PCR, cultures] to identify a specific agent.) At either 
point when positive IHC results are obtained (3), targeted PCR is performed for further identification when available, and a final diagnosis of agent-specific pneumonia is made 
when possible. If an etiologic agent is not identified by IHC or PCR testing (4), a diagnosis of “bronchopneumonia with no agent detected” is made. If special stains are neg-
ative (NEG) (left side of algorithm) (5), IHC is performed for any potentially relevant agents detected in lung TAC; positive IHC results (6) confirm agent-specific pneumonia. If 
no agents are detected on lung TAC or TAC results are not available, or if IHC for agents detected in lung TAC is negative (7), then screening by IHC for Streptococcus species 
and select GN bacteria is performed. If positive (8), targeted PCR is performed for further identification and a diagnosis of agent-specific pneumonia is made. If Streptococcus 
species and select gram-negative bacterial IHC is negative (9), then paneubacterial 16S PCR is performed as needed to attempt bacterial identification. #Targeted PCR is 
performed when available.
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Figure 3. Algorithm for evaluation of infectious etiology in lungs with interstitial pneumonia in minimally invasive tissue samples from children aged <5 years. Interstitial 
pneumonia is characterized by lymphocytic interstitial lymphocytes and/or diffuse alveolar damage (hyaline membranes, type II pneumocyte hyperplasia) and prompts evalua-
tion for primarily viral etiologies in infants >2 weeks. (*Some causes of bacterial sepsis, particularly Neisseria meningitidis, should also be considered in cases of lymphocytic 
interstitial pneumonitis.) If histopathologic features of specific viruses (eg, characteristic viral inclusions or syncytia) are seen (1), then a diagnosis of agent-specific viral 
pneumonia is made. If clinical history indicates duration of illness <1 week, immunohistochemistry (IHC) may be performed for further confirmation. If features of a specific 
virus are not seen (2), then age at death and gestational age (GA) at birth are critical to further interpretation of lung findings. If the infant was >2 weeks old at death, and 
GA at birth was >28 weeks (3), polymerase chain reaction (PCR) testing for respiratory viruses (influenza A/B, parainfluenza viruses 1–4, and respiratory syncytial virus) is 
performed on the formalin-fixed, paraffin-embedded tissue. Detection of other respiratory viruses in lung TaqMan Array Cards should prompt testing for those agents. Positive 
PCR leads to a diagnosis of agent-specific viral pneumonia (4), whereas negative PCR (5) results in a diagnosis of interstitial pneumonitis without infectious agent identified 
and consideration of noninfectious causes of childhood interstitial lung disease. If the infant was <2 weeks old at the time of death, and GA at birth was <28 weeks (6), the 
presence of hyaline membranes, with or without type II pneumocyte hyperplasia, is compatible with a diagnosis of infant respiratory distress syndrome (hyaline membrane di-
sease). #Targeted PCR is performed when available. Abbreviations: CMV, cytomegalovirus; GA, gestational age; HSV, herpes simplex virus; IHC, immunohistochemistry; NEG, 
negative; PCR, polymerase chain reaction; POS, positive; RSV, respiratory syncytial virus; RT-PCR, reverse-transcription polymerase chain reaction; TAC, TaqMan Array Card.
findings compatible with a particular syndrome and testing pro-
ceeds from less specific methods (eg, special stains to identify 
presence of bacteria, fungi) to more agent-specific methods (ie, 
IHC for specific agents or groups of agents). Targeted (group- or 
pathogen-specific), conventional (with amplicon sequencing), 
or real-time PCR/reverse-transcription (RT) PCR assays are 
utilized for confirmation of specific microorganisms detected by 
other less specific methods or when sensitivity of IHC is known 
to be lower than PCR (eg, respiratory viral infections without 
viral cytopathic effect observed on hematoxylin and eosin 
[H&E]–stained slides), and paneubacterial 16S ribosomal RNA 
gene PCR, followed by Sanger sequencing, is utilized for tissues 
where a bacterial agent is highly suspected but not detected by 
other methods. In such cases, if an agent is detected by broad-
range PCR, targeted IHC and/or PCR may then be performed; 
thus, there may be potential for multiple “feedback loops” within 
algorithms. Site-specific modifications to algorithms are also 
made when geographic trends in infectious disease are identi-
fied. For example, detection of a large number of nosocomial 
Acinetobacter baumannii infections at 1 CHAMPS site by tissue-
based PCR led to addition of routine IHC screening for this 
agent in all cases of acute bronchopneumonia from that site.
Pneumonia: Bronchopneumonia and Interstitial Pneumonia
Pneumonia due to viral and/or bacterial agents is the single 
most common cause of death in children worldwide, is most 
prevalent in South Asia and sub-Saharan Africa [12], and is the 
most frequent histopathologic finding in CHAMPS cases to 
date (data not published). Identification of the specific agents 
associated with childhood pneumonias is important for public 
health surveillance and disease control, and for development 
of effective diagnostic, therapeutic, and prophylactic protocols 
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[13–16]. Evaluation of postmortem lung tissue might confirm 
antemortem microbiological diagnoses, but more importantly, 
through demonstration of agents within lesions in the tissue, 
can help to distinguish causative agents from contaminants, 
false positives, or postmortem bacterial overgrowth, and can 
assess the relative contribution of different agents in cases of 
polymicrobial infection [17].
Bronchopneumonia is most commonly associated with bac-
terial etiologies, and the algorithm begins with identification 
of neutrophilic infiltrates in conducting airways (bronchi and 
bronchioles) and/or alveoli (Figure 2). If agents are not detected 
on TAC or Gram stain, IHC testing for Streptococcus species 
and select gram-negative bacteria (most pertinently Klebsiella 
pneumoniae) is performed to rule out these common causes 
of childhood pneumonia. The select gram-negative bacterial 
IHC assay uses an antibody raised against K. pneumoniae but 
is known to be broadly cross-reactive with other gram-negative 
bacteria of relevance to CHAMPS cases, including but not lim-
ited to Escherichia coli, Pseudomonas species, and Haemophilus 
influenzae. Of note, IHC may be more sensitive than Gram 
stain for bacterial detection in patients who received antibiotic 
treatment. If these agents are not detected by IHC, broad-range 
paneubacterial 16S PCR assays may be performed. IHC is per-
formed in cases of noncontributory Gram stain results because 
previous antibiotic therapy can diminish or alter the Gram 
staining characteristics of bacteria.
The interstitial pneumonia algorithm begins with iden-
tification of a pulmonary interstitial lymphocytic infiltrate 
(Figure 3) and/or diffuse alveolar damage (evidenced by hy-
aline membranes and/or type II pneumocyte hyperplasia). 
Consideration of the child’s age and gestational age at birth 
are critical when navigating this algorithm, as the noninfec-
tious condition infant respiratory distress syndrome (IRDS; 
hyaline membrane disease), which is common in the first few 
weeks of life in premature infants with surfactant deficiency, 
can histomorphologically resemble an infectious pneumonia 
seen in older infants. After exclusion of IRDS, the inter-
stitial pneumonia algorithm targets primarily viral agents. 
Histopathologic features of specific viruses (eg, syncytia and 
inclusions) direct to testing for these agents (Figure 7C); 
otherwise, histopathologic findings are nonspecific and so 
RT-PCR assays for some of the childhood respiratory viruses 
Figure 4. Algorithm for evaluation of brain samples with histopathologic diagnosis of meningitis or meningoencephalitis in minimally invasive tissue samples from chil-
dren aged <5 years. Meningitis and meningoencephalitis are characterized by detection of cellular infiltrates in the meninges and brain parenchyma, and the character of 
the infiltrate directs diagnostic testing. Neutrophilic infiltrates prompt consideration of primarily bacterial etiologies, and initial immunohistochemical (IHC) testing should be 
performed for agents detected in other tissues (lung, liver, cerebrospinal fluid [CSF], blood) by IHC or TaqMan Array Card (TAC) (1). Strong consideration should be given to 
agents detected in CSF by TAC. If agents are not detected in other tissues or CSF TAC is negative or not available, or if agents detected in CSF TAC are negative by IHC (2), then 
screening by IHC for Streptococcus species and select gram-negative bacteria is performed. If at any point positive IHC results are obtained (3), targeted polymerase chain re-
action (PCR) assays are performed on the formalin-fixed, paraffin-embedded tissue for further identification and a diagnosis of agent-specific meningitis/meningoencephalitis 
is made when possible. If an agent is not detected by IHC (4), the diagnosis is meningitis/meningoencephalitis, no agent identified. Nonsuppurative infiltrates warrant testing 
for other bacteria and nonbacterial agents, or consideration of neoplasia. Granulomatous infiltrates (5) direct to testing by special stains, IHC, and/or PCR for mycobacteria 
and fungi, whereas lymphoplasmacytic infiltrates (6) prompt more consideration of viral and protozoal agents (especially Toxoplasma, rubella, cytomegalovirus, herpesviruses, 
Treponema, and Zika). Cellular infiltrates with features of neoplasia (7) should be characterized by appropriate IHC if warranted and available, and other tissues reviewed for 
evidence of neoplasia. #Targeted PCR is performed when available. Abbreviations: CSF, cerebrospinal fluid; GMS, Grocott methenamine silver; IHC, immunohistochemistry; 
NEG, negative; PCR, polymerase chain reaction; POS, positive; TAC, TaqMan Array Card; TORCHZ, Toxoplasma, rubella, cytomegalovirus, herpesviruses, Treponema, and Zika; 
ZNAFB, Ziehl-Neelsen acid-fast bacilli stain.
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Figure 5. Algorithm for evaluation of tissue samples with histopathologic diag-
nosis of sepsis or clinical and laboratory suspicion of sepsis in minimally invasive 
tissue sampling (MITS) specimens from children aged <5  years. Histopathologic 
features of sepsis in MITS samples include hepatic sinusoidal leukocytosis, acute 
interstitial pneumonitis, or neutrophilic intravascular leukocytosis in any tissue. If 
these features are seen (left side of algorithm) (1), then immunohistochemical (IHC) 
testing should be performed on liver and other tissues with histopathologic features 
of sepsis for agent(s) detected on blood culture and/or TaqMan Array Card (TAC), if 
available (2). Positive (POS) IHC results confirm sepsis due to that agent (3). If blood 
culture and TAC results are negative (NEG) or not provided, or if IHC testing for 
agents detected by blood culture/TAC are negative (4), screening by Gram stain and 
IHC for Streptococcus species and select gram-negative bacteria are performed. If 
IHC is positive (5), targeted polymerase chain reaction (PCR) assays for identification 
of agent and/or further speciation are performed. If an agent is not confirmed by IHC 
(6), the diagnosis is limited to the histopathologic features observed (eg, hepatic si-
nusoidal leukocytosis, intravascular leukocytosis); a diagnosis of sepsis is not made 
unless bacteria are demonstrated by IHC. If histopathologic features of sepsis are 
not present in any tissue, but a relevant agent is detected on blood culture and/or 
TAC (7), correlation with clinical features is recommended and then testing of liver 
by IHC for that agent is performed only if the clinical history is compatible with 
known or suspected sepsis (8). #Targeted PCR is performed when available. 
(influenza A/B, parainfluenza 1–4, and respiratory syncytial 
virus) are performed on RNA extracts from the FFPE tissues. 
Noninfectious causes of childhood interstitial lung disease 
must also be considered, though these diagnoses must take 
into account genetic, clinical, and other diagnostic informa-
tion [18], which is often not available for CHAMPS cases.
Meningitis/Meningoencephalitis
Acute bacterial meningitis remains a significant cause of pe-
diatric illness and death in low- and middle-income coun-
tries [19]. Detection of neutrophilic infiltrates in meninges or 
brain parenchyma is the most common histologic finding and 
directs testing toward primarily bacterial agents (Figure 4). 
Detection of bacteria in other tissues may help point to specific 
agents early in the workup. Nonsuppurative infiltrates warrant 
consideration of other bacteria and fungi, viral and protozoal 
agents, or neoplastic disease, depending on the character of the 
infiltrate.
Sepsis
Despite major advances in neonatal care and increasing re-
search into neonatal sepsis, in developed countries, 40% of in-
fants with sepsis die or experience major disability including 
significant permanent neurodevelopmental impairment [20, 
21]. Prematurely born neonates experience the highest inci-
dence of, and mortality from, sepsis among all age groups [20, 
22, 23]. Histopathologic identification of hepatic sinusoidal 
leukocytosis, pulmonary interstitial pneumonitis, or neutro-
philic intravascular leukocytosis in any tissue warrants testing 
for sepsis (Figure 5). Even in the absence of histopathologic 
features of sepsis, testing for agents detected by blood culture 
or TAC performed on fresh MITS specimens should be con-
sidered, especially in cases where another significant bacterial 
process (eg, pneumonia, meningitis) is detected or when clin-
ical information strongly suggests sepsis. Demonstration of 
bacteria in sinusoids and/or Kupffer cells in the liver, or within 
vessels in any tissue, is sufficient for the histopathologic diag-
nosis of sepsis (Figure 7G), and testing may also be performed 
in other tissues with relevant histomorphologic features de-
scribed above. When TAC, culture, or other tissue pathology 
does not aid in guiding testing for specific agents, liver is tested 
by IHC for Streptococcus species and select gram-negative bac-
teria in cases of highly suspected sepsis. Targeted PCR testing 
follows if positive results are obtained.
Aspiration in Stillbirths and Early Neonate Deaths
Stillbirth and neonatal death can be difficult to understand and 
prevent due to the complex relationship between biological, so-
cial, and healthcare factors. Currently, two-thirds of deaths among 
infants occur within the first month of life (neonatal mortality), 
and around 50% of all deaths in the first year happen during the 
first week of life (early neonatal mortality) [24]. Aspiration of am-
niotic fluid indicates intrauterine fetal distress (IUFD) and can be 
a major contributing factor to stillbirth and neonatal mortality 
(Figure 6). It is evidenced histopathologically by detection of 
squames and/or meconium in the fetal or neonatal lung, and can 
be associated with infectious (eg, chorioamnionitis) or noninfec-
tious (eg, placental insufficiency) causes. While rare individual 
squames in the lung are considered an insignificant finding, the 
presence of at least moderate squames, or any amount of meco-
nium, is pathologic and warrants a diagnosis of IUFD (Figure 
7H). IUFD alone is often not associated with inflammation; 
therefore, if alveolar inflammation is seen, the algorithm directs 
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toward workup to exclude an infectious etiology (ie, broncho-
pneumonia algorithm). Also imperatively, evidence of IUFD or 
bronchopneumonia in the fetal or neonatal lung directs to ex-
amination of the placenta, fetal membranes, and umbilical cord 
for evaluation of chorioamnionitis or funisitis as the cause of as-
cending, in utero infection.
ACHIEVING A DIAGNOSIS FROM MITS: 
CORRELATION OF HISTOPATHOLOGY, LABORATORY 
TESTING, AND CLINICAL HISTORY
The end product of the algorithmic histopathologic exami-
nation and laboratory testing of MITS cases is the CPL final 
pathology report, which incorporates macroscopic and micro-
scopic descriptions of MITS specimens, results of special stains, 
IHC stains, molecular tests, final diagnoses, and a comment 
on clinicopathologic correlation to assist the Determining the 
Cause of Death (DeCoDe) panel in interpreting the significance 
of overall findings (see Blau et al in this supplement). In par-
allel, a separate final report is generated by the site pathologist 
detailing microscopic findings and limited ancillary testing (ie, 
special stains) performed on MITS specimens processed on 
site. The pathologists must consider the types and severity of 
histopathologic findings, together with the type(s) of agents de-
tected, in order to speculate on their relative contributions to 
the death. The clinical history, including signs and symptoms, 
immunostatus (eg, human immunodeficiency virus infection), 
treatments provided, and maternal history and gestational age, 
is crucial to interpretation of pathologic findings.
TELEPATHOLOGY: VIRTUAL DISCUSSIONS TO 
ACHIEVE CONSENSUS DIAGNOSES, TRAINING, AND 
QUALITY ASSURANCE
Telepathology is an emerging field utilizing digital communi-
cation technology and whole slide imaging (WSI) to transmit 
Figure 6. Algorithm for evaluation of aspiration in stillbirths or early neonates in minimally invasive tissue samples from the Child Health and Mortality Prevention 
Surveillance (CHAMPS) network from children aged <5 years. The presence of squames and/or meconium in the lungs of stillbirths or neonates indicates in utero amniotic 
fluid aspiration and warrants special consideration of potential causes, including placental evaluation for evidence of in utero infection or placental abnormalities. The 
presence of only rare squames without meconium is considered an insignificant finding (1), whereas the presence of moderate or abundant squames, and any amount of 
meconium, indicates intrauterine fetal distress (IUFD) and prompts evaluation of placental and umbilical cord tissues (2). If neutrophilic inflammation accompanies squames/
meconium in the lung (3), the bronchopneumonia algorithm (Figure 2) should also be initiated to investigate for infectious etiologies. If placenta and umbilical cord are 
not available (4), then the diagnosis is limited to IUFD. If placenta and umbilical cord have no inflammation (5), they are evaluated for potential noninfectious causes of 
IUFD (eg, placental infarct). If these tissues do have inflammation (6), evaluation for infectious agents by special stains and immunohistochemistry including screening for 
Streptococcus species and select gram-negative bacteria is performed. Agents detected on lung, blood, or cerebrospinal fluid TaqMan Array Card should be prioritized for 
testing in the placenta. If agents are not identified (7), a diagnosis of chorioamnionitis/funisitis, no agent identified is made. If an agent is identified (8), the agent associated 
with chorioamnionitis/funisitis should also be tested for in the lung tissue. #Targeted PCR is performed when available. Abbreviations: IHC, immunohistochemistry; IUFD, 
intrauterine fetal distress; NEG, negative; PCR, polymerase chain reaction; POS, positive; TAC, TaqMan Array Card.
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digital versions of glass slides for long-distance, real-time dis-
cussions and consultations for diagnosis, second opinion, or 
educational purposes [25–27]. WSI, captured on slide scanners, 
can be stored, organized, annotated, and transmitted digit-
ally, even to remote areas. The contribution of telepathology 
is especially relevant in remote locations that lack specialists 
and/or access to advanced testing methods (eg, special stains, 
IHC) [28], and provides opportunities for pathologists to par-
ticipate in collaborative review of cases and research over dis-
tances. While several studies have demonstrated the utility of 
telepathology using WSI as an effective diagnostic modality 
in surgical pathology, mostly for neoplastic diseases, only rare 
studies have evaluated its utility for infectious disease diagnoses 
[27, 29–32]. CHAMPS is unique in that it is the largest pro-
spective multicenter surveillance study utilizing MITS, and the 
first to implement telepathology primarily for identification of 
infectious causes of death.
The CHAMPS network is building an internet-based 
telepathology platform to connect pathologists from each of the 
sites and expert consultants from the CPL, to facilitate joint re-
view of cases to reach consensus diagnoses. Within CPL, glass 
slides of MITS cases, including H&Es, special stains, and IHC, 
are scanned primarily using a large capacity scanner (Leica 
Aperio AT2) and the associated scanner acquisition software. 
The resulting WSI is transferred to the CHAMPS servers, where 
image viewing and annotation of significant findings occurs 
Figure 7. Common histologic patterns seen in minimally invasive tissue samples. A, Lung tissue shows alveolar spaces with neutrophilic inflammation (bronchopneu-
monia). B, Lung tissue shows expansion of alveolar septa by inflammatory infiltrates (interstitial pneumonitis). C, Lung tissue shows alveolar space with pneumocytes 
containing viral inclusions (cytomegalovirus infection; arrows indicate infected cells). D, Lung tissue shows hyaline membranes (arrow) lining alveoli in infant respiratory 
distress syndrome (hyaline membrane disease). E, Brain tissue shows neutrophilic meningitis (arrow). F, Brain tissue shows perivascular infiltrate of neoplastic lymphocytes 
in a child with lymphoma/leukemia (arrow). G, Liver tissue shows moderate extramedullary hematopoiesis and small clusters of bacteria in sinusoids (arrow). H, Lung tissue 
shows intra-alveolar squames (arrowhead) and meconium ball (arrow) in intrauterine fetal distress. I, Lung tissue shows intra-alveolar bacterial colonies (arrow) without 
inflammation compatible with aspiration.
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(Supplementary Figure 2). All CHAMPS sites are equipped 
with a single slide scanner (NanoZoomer-SQ Digital slide 
scanner C131140-01- 40× mode-Hamamatsu) that generates 
WSI that can be viewed at magnifications up to 40×. At each 
site, a CHAMPS study technician is trained to scan the slides 
and transfer to the digital management system (Hamamatsu), 
where the program office information technology specialist up-
loads the WSI, provides the specific identification, and manages 
the image access for the project participants.
After training the pathologists on how to access and anno-
tate digital slides in the CHAMPS central server, telepathology 
sessions between site and CPL pathologists were initiated. Since 
September 2017, the CPL has conducted approximately monthly 
sessions with each of the 4 sites. The primary goal at each ses-
sion is to discuss discrepancies between site and CPL findings 
and reach a consensus diagnosis for each case by reviewing the 
digital images associated with cases of interest (Table 1). It is im-
portant to note that sites and CPL receive separate MITS speci-
mens from each case, and discrepancies between tissue findings 
may therefore be real, due to variability in presence of lesions 
among the specimens. The goal of telepathology is therefore 
overall consensus diagnoses for the case as a whole, not neces-
sarily consensus between site and CPL findings for each tissue 
type. The case discussions and consensus diagnoses are docu-
mented in a telepathology report that is made available to the 
DeCoDe panel to assist in interpreting overall pathologic find-
ings. Through these case discussions, pathologists are simulta-
neously trained on assessment of tissue section adequacy and 
quality, interpretation of histopathologic findings, utilization 
of diagnostic algorithms, and standardization of microscopic 
diagnoses. Due to the high volume of CHAMPS cases, only a 
subset are chosen for telepathology review, with an emphasis 
on those with highly discrepant site/CPL results or those that 
showcase important diagnoses or learning opportunities. An 
overview of the telepathology case selection and consultation 
process is provided in Table 1, and a sample telepathology re-
port is shown in Supplementary Figure 3.
The value of telepathology in CHAMPS is not limited to 
achieving consensus diagnoses; it is also vital to the CHAMPS 
goal of increasing local pathology capacity and expertise at sites. 
Scanned slides are evaluated for tissue adequacy (eg, amount of 
target tissue obtained, autolysis) and slide preparation quality 
(eg, thickness, tissue folds, staining quality, coverslipping) at the 
same time as evaluation for pathologic processes. While initial 
training activities incorporated targeted quality assessments of 
histology procedures by review of slides through telepathology 
(see Rakislova et al in this supplement), this ongoing quality as-
sessment will be critical throughout the duration of CHAMPS, 
especially as increased capacity is transferred from the CPL to 
the sites.
In addition to technical quality assessment, telepathology 
facilitates training of pathologists in identification of patho-
logic processes in tissues. The telepathology platform allows for 
both real-time instruction during telepathology sessions, and 
for historical review of annotated case materials for future and 
repeated reference. To this end, the CPL is in the process of de-
veloping a more formal training module that will contain an-
notated slides with examples of characteristic histopathologic 
patterns of disease, along with explanation of ancillary testing 
and interpretation of results. This module will be available 
within CHAMPS and will be an invaluable tool for pathologists 
and trainees.
DISCUSSION
While a full postmortem examination provides the greatest 
ability to determine the mechanism and/or cause of death, the 
use of MITS provides a significant opportunity to obtain sim-
ilar information in cases where a complete diagnostic autopsy 
is not possible. Histopathologic evaluation of MITS and dem-
onstration of infectious agents directly associated with tissue 
pathology, together with clinical information, is crucial to 
interpreting significance of findings. Testing (TAC, culture) of 
unfixed MITS specimens is helpful for guiding histopathologic 
testing, but can also result in extraneous results due to detec-
tion of commensals or contaminants that are noncontributory 
toward mortality. As such, the development of testing algo-
rithms for common histologic findings in CHAMPS cases has 
been necessary for consistent, thorough evaluation of MITS 
specimens. It is important to note that these algorithms do not 
encompass every possible infectious etiology associated with 
Table 1. Summary of Telepathology Case Selection and Consultation 
Process in the Child Health and Mortality Prevention Surveillance 
Network
Telepathology case selection and consultation process
• 1-hour session scheduled monthly between site and CPL.
•  CPL identifies cases for which both site and CPL histopathology  
reports are available.
•  CPL compares site and CPL reports for major discrepancies or  
important diagnoses and learning opportunities. Sites are also invited 
to suggest cases for discussion. Up to 10 cases are chosen for review 
at each session.
• CPL notifies sites of cases slated for telepathology session.
•  Both CPL and sites upload scanned slides (hematoxylin and eosin, 
special stains, immunohistochemistry) into CHAMPS central server 
and annotate significant histopathologic findings. CPL and sites have 
access to both sets of slides and can review and annotate each 
other’s slides to indicate areas for discussion.
•  Telepathology session is conducted through online video conferencing 
with screen sharing for simultaneous viewing of whole slide images 
by sites and CPL. CPL provides clinical history and laboratory data for 
each case, then site and CPL findings are discussed in real time while 
viewing the slides. Discussion points and consensus diagnoses are 
documented in the telepathology report form during the session.
•  CPL generates the final telepathology report and uploads to CHAMPS 
portal for inclusion in DeCoDe packet.
Abbreviations: CHAMPS, Child Health and Mortality Prevention Surveillance; CPL, Central 
Pathology Laboratory; DeCoDe, Determination of Cause of Death panel.
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Table 2. Telepathology Challenges
Challenges Examples
Technical Setup and maintenance of scanners and servers 
 Digital file management
Secure file sharing 
 Internet connections
Pathologist proficiency in viewing digital slides
 Quality of scanned slides/pixilation
Logistical Time delay for scanning digital slides and annotation
 Coordination of schedules in multiple time zones for slide 
review and telepathology sessions
Interpersonal Language barriers
 Working as a group to establish rapport between Central 
Pathology Laboratory and sites 
a particular histopathologic pattern; they represent general 
guidelines that have been found to be effective and efficient for 
identifying infections within the context of the CHAMPS study 
thus far. Furthermore, there are important histopathologic 
findings that are not incorporated into the algorithms, as they 
alone warrant consideration of specific infectious agents (eg, 
granulomas in any tissue warrants testing for mycobacterial 
and fungal agents). The algorithmic approach is modified/ex-
panded on a case-by-case basis, taking into consideration fac-
tors such as clinical history, results of other laboratory testing, 
and geographic trends in infectious diseases. The algorithms 
have evolved as we have gained a greater understanding of the 
causes of childhood mortality and how to best diagnose them 
utilizing our available testing modalities, and they will no doubt 
continue to change as we further this endeavor.
While able to provide valuable information regarding causes 
of death, utilization of MITS specimens presents a number of 
technical challenges, the first of which is obtaining an adequate 
target tissue sample. For CHAMPS, MITS procedures are per-
formed in low-resource settings and within limited time con-
straints, and are therefore done without imaging assistance 
to ensure targeted tissue/lesion collection. In some instances, 
especially stillbirths or small neonates, a sufficient amount of 
target tissue may not be obtained. Even if the target tissue is 
obtained, focal or small lesions may be missed (eg, focal lung 
abscess), and samples may therefore not be representative of 
pathologic processes present. Contamination of MITS by un-
intentionally collected tissues, such as gastrointestinal tissues in 
liver samples or nasal contents in transnasal brain samples, may 
introduce bacterial contaminants that complicate interpretation 
of ancillary tests. Furthermore, the MITS procedure does not 
target some organs that may be most relevant to determining 
cause of death (eg, structural cardiac abnormalities, gastroin-
testinal disease).
When target tissue is obtained, additional factors may con-
tribute to a suboptimal sampling. Some examples include au-
tolysis (especially in macerated fetuses), postmortem bacterial 
overgrowth, absence of pertinent anatomical components such 
as meninges in brain specimens or conducting airways in lung, 
and iatrogenic atelectasis in lung specimens. The small size of 
MITS specimens also sometimes results in tissue depletion 
when multiple IHC or PCR assays are needed. This can be espe-
cially challenging in cases where clinical history or fresh tissue 
test results are not available to help narrow testing early in the 
evaluation of a case.
Finally, achieving consistent diagnoses across pathologists 
and CHAMPS sites requires standardization of interpretation 
of histopathologic findings, with careful consideration of all test 
results available. TAC and IHC results are initially considered 
together to determine which of the identified pathogens, if any, 
are most likely contributing to the histopathologic changes 
seen, and ultimately to the cause of death. TAC may produce 
both pertinent and extraneous results and IHC assays are fre-
quently broadly cross-reactive; therefore, considering both TAC 
and IHC together yields stronger confidence to diagnosis or ex-
clusion of specific pathogens. Targeted PCR with sequencing on 
FFPE tissues can further confirm or help to exclude pathogens 
detected by TAC/IHC, and paneubacterial 16S PCR is valuable 
as a screening tool in cases with high suspicion for infection 
when other, less sensitive methods do not yield pathogens. 
Standardization not only of the diagnostic workup for cases, but 
also of the interpretation of potentially complex aggregate re-
sults, is challenging but crucial to accurately identifying infec-
tious causes of death.
Telepathology facilitates standardization of diagnoses and 
training of pathologists and allows for continuous quality assess-
ment during transfer of pathology capacity from CPL to sites. 
Though telepathology is an invaluable asset that enables virtual 
consultations, it is not without challenges, including those that 
are technical, logistical, and interpersonal, as briefly summar-
ized in Table 2. Ultimately, CHAMPS and the telepathology 
platform will facilitate the development of a worldwide, col-
laborative network of pathologists with expertise in utilizing 
MITS for identifying causes of childhood mortality, and will 
lead to the implementation of mortality-reducing measures in 
CHAMPS, and potentially other, sites.
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